These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9230511)

  • 21. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSA level changes over time in men with an initial PSA level of < or = 4 ng/ml.
    Bangma C
    Nat Clin Pract Urol; 2006 Oct; 3(10):520-1. PubMed ID: 17031372
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate-specific antigen: current status.
    Lukes M; Urban M; Záleský M; Zachoval R; Herácek J; Zdárský E
    Folia Biol (Praha); 2001; 47(2):41-9. PubMed ID: 11321246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 27. [Legal (liability) aspects of PSA determination].
    Mielke K
    Urologe A; 2006 Jun; 45(6):756-65. PubMed ID: 16788794
    [No Abstract]   [Full Text] [Related]  

  • 28. AUA issues a policy report on PSA monitoring. The American Urological Association.
    Scott Morey S
    Am Fam Physician; 2000 Aug; 62(4):883-4. PubMed ID: 10969861
    [No Abstract]   [Full Text] [Related]  

  • 29. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
    J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pro PSA: a new prostate cancer marker].
    Peyromaure M
    Prog Urol; 2004 Sep; 14(4 Suppl):8-11. PubMed ID: 15776578
    [No Abstract]   [Full Text] [Related]  

  • 31. PSA: prostate-specific antigen, persisting scientific ambiguities.
    Harv Mens Health Watch; 2009 Jul; 13(12):1-6. PubMed ID: 19718841
    [No Abstract]   [Full Text] [Related]  

  • 32. Early detection of prostate cancer: is PSA a reliable option?
    Okihara K; Babaian RJ
    Tex Med; 2001 Feb; 97(2):59-62. PubMed ID: 11233061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
    Stephan C; Cammann H; Meyer HA; Lein M; Jung K
    Cancer Lett; 2007 Apr; 249(1):18-29. PubMed ID: 17292541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Has there been a change in practice of screening for prostate cancer with prostate-specific antigen in Ontario?
    Bunting PS
    Clin Biochem; 2004 Oct; 37(10):898-903. PubMed ID: 15369721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prostate carcinoma: prostate-specific antigen--and then what?].
    Schmid HP
    Ther Umsch; 1998 Jul; 55(7):426-8. PubMed ID: 9702110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is prostate-specific antigen still the best tumor marker for prostate cancer?
    Leewansangtong S; Soontrapa S; Tantiwong A
    J Med Assoc Thai; 1999 Oct; 82(10):1034-40. PubMed ID: 10561969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group.
    Greiver M; Rosen N
    CMAJ; 2000 Mar; 162(6):789-90. PubMed ID: 10750465
    [No Abstract]   [Full Text] [Related]  

  • 39. [PSA density, PSA velocity and PSA doubling time].
    Kurokawa K
    Nihon Rinsho; 2000 Jul; 58 Suppl():103-7. PubMed ID: 11022694
    [No Abstract]   [Full Text] [Related]  

  • 40. [Prostate cancer].
    Uchida K; Akaza H
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.